Redmile Group, LLC 的 Form 4 申報
Fate Therapeutics IncFATE，2023/4/21 申報
- 申報編號
- 0001104659-23-048557
- 申報時間
- 2023/4/21 21:55 ET
- 交易日
- 2023/4/20-4/21
- 申報延遲
- 1 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 2 筆非衍生性交易。公開市場買進合計 $170.6 萬。交易後 1 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Redmile Group, LLCCIK 0001425738 | 董事、持股 10% 以上大股東 |
| Green JeremyCIK 0001650527 | 董事、持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.995 to $6.00, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F2
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.99 to $6.22, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
備註
Mr. Michael Lee, a member of the board of directors of the Issuer and a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile. As a result, the Reporting Persons are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.